Home Cart Sign in  
Chemical Structure| 1193-24-4 Chemical Structure| 1193-24-4

Structure of 4,6-Dihydroxypyrimidine
CAS No.: 1193-24-4

Chemical Structure| 1193-24-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 1193-24-4 ]

CAS No. :1193-24-4
Formula : C4H4N2O2
M.W : 112.09
SMILES Code : OC1=CC(O)=NC=N1
MDL No. :MFCD00016733
InChI Key :DUFGYCAXVIUXIP-UHFFFAOYSA-N
Pubchem ID :14512

Safety of [ 1193-24-4 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 1193-24-4 ] Show Less

Physicochemical Properties

Num. heavy atoms 8
Num. arom. heavy atoms 6
Fraction Csp3 0.0
Num. rotatable bonds 0
Num. H-bond acceptors 4.0
Num. H-bond donors 2.0
Molar Refractivity 26.08
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

66.24 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.05
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

0.16
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

-0.11
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

-0.9
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

0.1
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

0.06

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-1.19
Solubility 7.22 mg/ml ; 0.0645 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-1.11
Solubility 8.74 mg/ml ; 0.0779 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-0.44
Solubility 40.5 mg/ml ; 0.361 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.87 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

2.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.37

Application In Synthesis of [ 1193-24-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 1193-24-4 ]

[ 1193-24-4 ] Synthesis Path-Downstream   1~54

  • 2
  • [ 90-46-0 ]
  • [ 1193-24-4 ]
  • [ 50278-49-4 ]
  • 3
  • [ 150-60-7 ]
  • [ 1193-24-4 ]
  • [ 138918-23-7 ]
  • 4
  • [ 58502-69-5 ]
  • [ 1193-24-4 ]
  • [ 141764-36-5 ]
YieldReaction ConditionsOperation in experiment
69% With 1,8-diazabicyclo[5.4.0]undec-7-ene; In ethanol; at 60℃;Heating / reflux;Product distribution / selectivity; The title compound 10 was prepared by the method of Dauzonne, D.; Adam-Launay,A. Tetrahedron 1992, 48, 3069-3080. 4,6-Dihydroxypyrimidine (3.3 g, 29.4 mmol) and (2-Chloro-2-nitro-vinyl)-benzene (5.3 g, 26.7 mmol) were combined in EtOH (absolute, 110mL) and the mixture was heated at 60 C for 10 min to dissolve 4,6-Dihydroxypyrimidine.DBU (8.06 mL, 53.9 mmol) was then added drop-wise to the reaction. After addition of DBUthe deep green-brown solution was heated at reflux for 3 h then at 60 C over night. The deepred solution was then cooled to room temperature and concentrated to a thick red oil.Purification by flash chromatography (SiO2, gradient eluent: CH2C12 to 5% MeOH/CH2Cl2) toafford crude 10 as an orange-red semisolid/oil. This material was triturated with 1.75:1CH2Cl2/hexanes and solid 10 was isolated by Buchner filtration. Flash chromatography of themother liquors afforded a second crop of solid 3 (>90% pure). The two crops were combinedand concentrated to afford 10.; Step 2: 5-PhenyI-3H-furo[2,3-d]pyrimidin-4-one (162)[0389] The title compound was prepared by the method of Dauzonne, D.; Adam-Launay, A.Tetrahedron 1992, 48, 3069-3080. 4,6-Dihydroxypyrimidine 161 (3.3 g, 29.4 mmol) and 160(5.3 g, 26.7 mmol) were combined in EtOH (absolute, 110 mL) and the mixture was heated at60C for 10 min to dissolve 161. DBU (8.06 mL, 53.9 mmol) was then added drop-wise.After addition of DBU the deep green-brown solution was heated at reflux for 3 h then at60C over night. The deep red solution was then cooled to room temperature andconcentrated to a thick red oil. Purification by flash chromatography (SiO2, gradient eluent:CH2C12 to 5% MeOH/CH2Cl2) to afford as an orange-red semisolid/oil. This material wastriturated with 1.75:1 CH2Cl2/hexanes and solid 162 was isolated by Buchner filtration (~95% pure). Flash chromatography of the mother liquors afforded a second crop of solid 162(>90% pure). The two crops were combined and concentrated to afford 162 as a pale orangesolid (69% yield).
  • 5
  • [ 58502-69-5 ]
  • [ 1193-24-4 ]
  • [ 141764-35-4 ]
  • 6
  • [ 127143-22-0 ]
  • [ 1193-24-4 ]
  • [ 141764-46-7 ]
  • 7
  • [ 127143-22-0 ]
  • [ 1193-24-4 ]
  • [ 141764-39-8 ]
  • 8
  • [ 65018-90-8 ]
  • [ 1193-24-4 ]
  • [ 129421-80-3 ]
  • 9
  • [ 127143-20-8 ]
  • [ 1193-24-4 ]
  • [ 141764-44-5 ]
  • 10
  • [ 127143-20-8 ]
  • [ 1193-24-4 ]
  • [ 141764-37-6 ]
  • 11
  • [ 127143-21-9 ]
  • [ 1193-24-4 ]
  • [ 141764-45-6 ]
  • 12
  • [ 127143-21-9 ]
  • [ 1193-24-4 ]
  • [ 141764-38-7 ]
  • 13
  • [ 127143-28-6 ]
  • [ 1193-24-4 ]
  • [ 141764-49-0 ]
YieldReaction ConditionsOperation in experiment
20% As in the procedure described in the literature [D. Dauzonne, Tetrahedron, 1992, 3069-3080], stir a suspension of 10.1 g (47.4 mmol) 1-[(Z)-2-chloro-2-nitrovinyl]-4-methoxybenzene and 5.8 g (52.2 mmol) <strong>[1193-24-4]4,6-dihydroxypyrimidine</strong> in 200 ml ethanol for ten minutes at 85 C. Next, slowly add 15.6 ml (15.9 g, 104.3 mmol) 1,8-diazabicyclo[5.4.0]undec-7-ene. Stir for 15 h at this temperature and then concentrate by vacuum evaporation. Take up the residue in dichloromethane and chromatograph on silica gel (solvent: dichloromethane/methanol 95:5). Mix the solid obtained with acetonitrile and then filter. 2.3 g (20% of theor.) of the target product is obtained. LC-MS (Method 2): Rt=1.57 min; m/z=290 (M+H)+ 1H-NMR (400 MHz, CDCl3): delta=12.66 (s, 1H), 8.15 (s, 1H), 8.14 (s, 1H), 7.92 (d, 2H), 6.98 (d, 2H), 3.79 (s, 3H).
20% Example 15A 5-(4-Methoxyphenyl)furo[2,3-d]pyrimidin-4(3H)-one Analogously to a literature procedure [D. Dauzonne, Tetrahedron, 1992, 3069-3080], a suspension of 10.1 g (47.4 mmol) of 1-[(Z)-2-chloro-2-nitrovinyl]-4-methoxybenzene and 5.8 g (52.2 mmol) of <strong>[1193-24-4]4,6-dihydroxypyrimidine</strong> in 200 ml of ethanol is stirred at 85 C. for ten minutes. 15.6 ml (15.9 g, 104.3 mmol) of 1,8-diazabicyclo[5.4.0]undec-7-ene are then added slowly. The mixture is stirred at this temperature for 15 h and then concentrated under reduced pressure. The residue is taken up in dichloromethane and chromatographed on silica gel (mobile phase: dichloromethane/methanol 95:5). The solid obtained is triturated with acetonitrile and filtered. This gives 2.3 g (20% of theory) of the target product. LC-MS (method 3): Rt=1.57 min.; m/z=290 (M+H)+ 1H-NMR (400 MHz, CDCl3): delta=12.66 (s, NH), 8.15 (s, 1H), 8.14 (s, 1H), 7.92 (d, 2H), 6.98 (d, 2H), 3.79 (s, 3H).
  • 14
  • [ 127143-28-6 ]
  • [ 1193-24-4 ]
  • [ 141764-42-3 ]
  • [ 141764-42-3 ]
  • 15
  • [ 127143-27-5 ]
  • [ 1193-24-4 ]
  • [ 141764-48-9 ]
  • 16
  • [ 127143-27-5 ]
  • [ 1193-24-4 ]
  • [ 141764-41-2 ]
  • 17
  • [ 127143-26-4 ]
  • [ 1193-24-4 ]
  • [ 141764-47-8 ]
  • 18
  • [ 127143-26-4 ]
  • [ 1193-24-4 ]
  • [ 141764-40-1 ]
  • [ 141764-40-1 ]
  • 19
  • [ 127143-25-3 ]
  • [ 1193-24-4 ]
  • [ 141764-53-6 ]
  • 20
  • [ 127143-25-3 ]
  • [ 1193-24-4 ]
  • [ 141764-33-2 ]
  • [ 141764-33-2 ]
  • 21
  • [ 127143-24-2 ]
  • [ 1193-24-4 ]
  • [ 141764-52-5 ]
  • 22
  • [ 127143-24-2 ]
  • [ 1193-24-4 ]
  • [ 141764-52-5 ]
  • [ 141764-31-0 ]
  • [ 141764-31-0 ]
  • 23
  • [ 127143-23-1 ]
  • [ 1193-24-4 ]
  • [ 141764-51-4 ]
  • 24
  • [ 127143-23-1 ]
  • [ 1193-24-4 ]
  • [ 141764-51-4 ]
  • [ 141764-29-6 ]
  • [ 141764-29-6 ]
  • 25
  • [ 127143-29-7 ]
  • [ 1193-24-4 ]
  • [ 141764-50-3 ]
  • 26
  • [ 127143-29-7 ]
  • [ 1193-24-4 ]
  • [ 141764-43-4 ]
  • 28
  • [ 1193-24-4 ]
  • [ 105163-90-4 ]
  • [ 105163-94-8 ]
  • C5H4N2O3(1-) [ No CAS ]
  • 30
  • [ 104-88-1 ]
  • [ 1193-24-4 ]
  • C15H11ClN4O4 [ No CAS ]
  • 31
  • [ 99-61-6 ]
  • [ 1193-24-4 ]
  • 5,5'-(3-nitrobenzylidene)bis(4,6-dihydroxypyrimidine) [ No CAS ]
  • 36
  • [ 1193-24-4 ]
  • [ 15164-44-0 ]
  • C15H11IN4O4 [ No CAS ]
  • 38
  • [ 1193-24-4 ]
  • [ 4316-93-2 ]
  • 40
  • [ 67-52-7 ]
  • [ 1193-24-4 ]
  • [ 59025-32-0 ]
  • 41
  • [ 27402-47-7 ]
  • [ 1193-24-4 ]
  • [ 59025-32-0 ]
  • 42
  • [ 27402-47-7 ]
  • [ 1193-24-4 ]
  • 5-(carbamoylacetylaminomethylene)barbituric acid [ No CAS ]
  • [ 155375-91-0 ]
  • 43
  • [ 90-02-8 ]
  • [ 1193-24-4 ]
  • 3,5-dihydro-4H-chromeno[4,3-d]pyrimidine-4,5-dione [ No CAS ]
  • [ 1846-78-2 ]
  • 44
  • [ 148-53-8 ]
  • [ 1193-24-4 ]
  • [ 1728-88-7 ]
  • N-formyl-8-methoxy-3-coumarincarboxamide [ No CAS ]
  • 45
  • [ 148-53-8 ]
  • [ 1193-24-4 ]
  • 5,5'-(3-methoxysalicyclidene)bis(4,6-dihydroxypyrimidine) [ No CAS ]
  • 46
  • [ 97-51-8 ]
  • [ 1193-24-4 ]
  • 6-nitro-2-oxo-2H-chromen-3-carboxamide [ No CAS ]
  • 6-nitro-10a<i>H</i>-9-oxa-2,4-diaza-phenanthrene-1,10-dione [ No CAS ]
  • 47
  • [ 2144-08-3 ]
  • [ 1193-24-4 ]
  • 7,8-dihydroxy-3-coumarincarboxamide [ No CAS ]
  • 48
  • [ 1193-24-4 ]
  • [ 1761-61-1 ]
  • [ 38472-56-9 ]
  • 49
  • [ 1193-24-4 ]
  • [ 1761-61-1 ]
  • [ 38472-56-9 ]
  • 9-bromo-3,5-dihydro-4H-chromeno[4,3-d]pyrimidine-4,5-dione [ No CAS ]
  • 50
  • [ 1193-24-4 ]
  • [ 1761-61-1 ]
  • 9-bromo-3,5-dihydro-4H-chromeno[4,3-d]pyrimidine-4,5-dione [ No CAS ]
  • 51
  • [ 1193-24-4 ]
  • [ 1761-61-1 ]
  • 6-bromo-N-(5-bromosalicylidene)-3-coumarincarboxamide [ No CAS ]
  • 52
  • [ 1193-24-4 ]
  • [ 1761-61-1 ]
  • 5,5'-(5-bromosalicyclidene)bis(4,6-dihydroxypyrimidine) [ No CAS ]
  • 53
  • [ 1193-24-4 ]
  • [ 90-60-8 ]
  • [ 101166-95-4 ]
  • 6-nitro-10a<i>H</i>-9-oxa-2,4-diaza-phenanthrene-1,10-dione [ No CAS ]
  • 54
  • [ 1193-24-4 ]
  • [ 90-60-8 ]
  • 5,5'-(3,5-dichlorosalicyclidene)bis(4,6-dihydroxypyrimidine) [ No CAS ]
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 1193-24-4 ]

Alcohols

Chemical Structure| 51953-18-5

A136378 [51953-18-5]

Pyrimidin-4-ol

Similarity: 0.78

Chemical Structure| 3709-98-6

A107138 [3709-98-6]

2-Ethyl-4,6-dihydroxypyrimidine

Similarity: 0.78

Chemical Structure| 16019-30-0

A267986 [16019-30-0]

5-Allylpyrimidine-4,6-diol

Similarity: 0.78

Chemical Structure| 1194-74-7

A249903 [1194-74-7]

4(1H)-Pyrimidinone,6-hydroxy-2,5-dimethyl-

Similarity: 0.76

Related Parent Nucleus of
[ 1193-24-4 ]

Pyrimidines

Chemical Structure| 5270-94-0

A194499 [5270-94-0]

4,6-Dimethoxypyrimidine

Similarity: 0.87

Chemical Structure| 40497-30-1

A253557 [40497-30-1]

2-Methylpyrimidine-4,6(1H,5H)-dione

Similarity: 0.85

Chemical Structure| 51953-18-5

A136378 [51953-18-5]

Pyrimidin-4-ol

Similarity: 0.78

Chemical Structure| 16019-30-0

A267986 [16019-30-0]

5-Allylpyrimidine-4,6-diol

Similarity: 0.78

Chemical Structure| 36315-01-2

A489915 [36315-01-2]

2-Amino-4,6-dimethoxypyrimidine

Similarity: 0.78